Drug or intervention
Rivaroxaban Clinical Trials
Studies that test Rivaroxaban, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 114Ischemic Stroke
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial…
- Trial name
- ARCHIMEDES (NCT06396858)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG
- Volunteers
- 4,500 people
- Sponsor
- Brazilian Clinical Research Institute
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Kawasaki Disease, Pilot Study
Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was…
- Conditions
- Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm, Rivaroxaban
- Trial name
- NCT06978439
- Testing
- Rivaroxaban (Xarelto)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Fudan University
Peripheral Artery Disease (PAD)
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become…
- Trial name
- ROXI-PALISADE (NCT07318610)
- Testing
- REGN7508, REGN9933, Rivaroxaban
- Where
- 29 sites in United States, United Kingdom
- Volunteers
- 7,050 people
- Sponsor
- Regeneron Pharmaceuticals
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Uterine Hemorrhage, Cardiovascular Diseases
A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular Surgery
This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery.
- Conditions
- Uterine Hemorrhage, Cardiovascular Diseases, Antithrombotic Drugs
- Trial name
- NCT07870941
- Testing
- antithrombotic drugs
- Where
- China
- Volunteers
- 1,308 people
- Sponsor
- Shanghai Zhongshan Hospital
Cerebral Venous Thrombosis
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
This prospective, single-arm observational cohort study aims to evaluate the real-world effectiveness and safety of direct oral anticoagulants (DOACs), specifically dabigatran or rivaroxaban, in patients with cerebral venous…
- Trial name
- DCVT-VN25 (NCT07083609)
- Testing
- Dabigatran, Rivaroxaban
- Where
- Vietnam
- Volunteers
- 69 people
- Sponsor
- Hieu Trung Dinh
Hip Fractures
HIP Fracture Oral thromboPROphylaxis (Hip PRO Pilot)
As our Canadian population ages, hip fractures in these older adults are becoming very common. The best treatment for the majority of these injuries is urgent treatment with surgery.
- Trial name
- HIP PRO Pilot (NCT05775965)
- Testing
- Rivaroxaban 10mg, acetylsalicylic acid (ASA) 81mg Oral Tablet
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- University of Calgary
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Completed, with results posted
All 73Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban.
- Trial name
- COBRRA Pilot (NCT02559856)
- Testing
- Apixaban, Rivaroxaban
- Where
- 4 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Venous Thromboembolism, Arthroplasty
Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT)…
- Trial name
- NCT05449327
- Testing
- Rivaroxaban 10 MG
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Chiayi Christian Hospital
Coronary Syndrome
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20 mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers, platelet function and arachidonic acid…
- Trial name
- WILLOW CCS (NCT04990791)
- Testing
- Aspirin 75mg, Aspirin 20mg, Rivaroxaban 2.5 mg
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust